Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chemotherapy Induced Nausea and Vomiting-Pipeline Review, H1 2015

Chemotherapy Induced Nausea and Vomiting-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chemotherapy Induced Nausea and Vomiting-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chemotherapy Induced Nausea and Vomiting-Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Nausea and Vomiting's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chemotherapy Induced Nausea and Vomiting and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chemotherapy Induced Nausea and Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chemotherapy Induced Nausea and Vomiting pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chemotherapy Induced Nausea and Vomiting Overview 8

Therapeutics Development 9

Pipeline Products for Chemotherapy Induced Nausea and Vomiting-Overview 9

Pipeline Products for Chemotherapy Induced Nausea and Vomiting-Comparative Analysis 10

Chemotherapy Induced Nausea and Vomiting-Therapeutics under Development by Companies 11

Chemotherapy Induced Nausea and Vomiting-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Chemotherapy Induced Nausea and Vomiting-Products under Development by Companies 17

Chemotherapy Induced Nausea and Vomiting-Companies Involved in Therapeutics Development 19

Acacia Pharma Ltd. 19

Aphios Corporation 20

Genovate Biotechnology Co., LTD. 21

Helsinn Holding S.A. 22

Heron Therapeutics, Inc. 23

INSYS Therapeutics, Inc. 24

Kyowa Hakko Kirin Co., Ltd. 25

Merck & Co., Inc. 26

RedHill Biopharma Ltd. 27

Shin Nippon Biomedical Laboratories, Ltd. 28

Sparsha Pharma International Pvt. Ltd. 29

Suda Ltd 30

Teikoku Pharma USA, Inc. 31

Tesaro, Inc. 32

Chemotherapy Induced Nausea and Vomiting-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Combination Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 42

(netupitant + palonosetron hydrochloride)-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

APD-403-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

APD-421-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

aprepitant-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

aprepitant-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

dronabinol-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

dronabinol-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Drug to Antagonize 5-HT3 for Chemotherapy Induced Nausea and Vomiting-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

granisetron-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

granisetron-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

granisetron ER-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

granisetron ER-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

ondansetron hydrochloride-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ondansetron hydrochloride-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

ondansetron hydrochloride CR-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

rolapitant hydrochloride-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

TPW-146-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Chemotherapy Induced Nausea and Vomiting-Recent Pipeline Updates 66

Chemotherapy Induced Nausea and Vomiting-Dormant Projects 80

Chemotherapy Induced Nausea and Vomiting-Discontinued Products 81

Chemotherapy Induced Nausea and Vomiting-Product Development Milestones 82

Featured News & Press Releases 82

Jan 12, 2015: Insys Therapeutics Plans to Submit NDA for Dronabinol Oral Solution in First Quarter of 2015 82

Jan 12, 2015: Insys Therapeutics To Initiate Phase III Pivotal PK Study For Ondansetron 82

Dec 31, 2014: RedHill Biopharma Announces Acceptance for Review of BEKINDA European Marketing Application for Oncology Support 82

Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 83

Nov 06, 2014: Heron Therapeutics Discloses HTX-019 Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV 85

Nov 06, 2014: Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV 85

Oct 10, 2014: FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy 86

Sep 27, 2014: Rolapitant Reduces Nausea and Vomiting in Phase III Trial 86

Sep 08, 2014: OPKO Licensee TESARO Submits New Drug Application for Rolapitant 87

Jul 10, 2014: Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA (netupitant 300mg + oral palonosetron 0.50mg), Will be Published in the Annals of Oncology 88

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 91

Disclaimer 91

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2015 9

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Comparative Analysis by Unknown Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Chemotherapy Induced Nausea and Vomiting-Pipeline by Acacia Pharma Ltd., H1 2015 19

Chemotherapy Induced Nausea and Vomiting-Pipeline by Aphios Corporation, H1 2015 20

Chemotherapy Induced Nausea and Vomiting-Pipeline by Genovate Biotechnology Co., LTD., H1 2015 21

Chemotherapy Induced Nausea and Vomiting-Pipeline by Helsinn Holding S.A., H1 2015 22

Chemotherapy Induced Nausea and Vomiting-Pipeline by Heron Therapeutics, Inc., H1 2015 23

Chemotherapy Induced Nausea and Vomiting-Pipeline by INSYS Therapeutics, Inc., H1 2015 24

Chemotherapy Induced Nausea and Vomiting-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 25

Chemotherapy Induced Nausea and Vomiting-Pipeline by Merck & Co., Inc., H1 2015 26

Chemotherapy Induced Nausea and Vomiting-Pipeline by RedHill Biopharma Ltd., H1 2015 27

Chemotherapy Induced Nausea and Vomiting-Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2015 28

Chemotherapy Induced Nausea and Vomiting-Pipeline by Sparsha Pharma International Pvt. Ltd., H1 2015 29

Chemotherapy Induced Nausea and Vomiting-Pipeline by Suda Ltd, H1 2015 30

Chemotherapy Induced Nausea and Vomiting-Pipeline by Teikoku Pharma USA, Inc., H1 2015 31

Chemotherapy Induced Nausea and Vomiting-Pipeline by Tesaro, Inc., H1 2015 32

Assessment by Monotherapy Products, H1 2015 33

Assessment by Combination Products, H1 2015 34

Number of Products by Stage and Target, H1 2015 36

Number of Products by Stage and Mechanism of Action, H1 2015 38

Number of Products by Stage and Route of Administration, H1 2015 40

Number of Products by Stage and Molecule Type, H1 2015 41

Chemotherapy Induced Nausea and Vomiting Therapeutics-Recent Pipeline Updates, H1 2015 66

Chemotherapy Induced Nausea and Vomiting-Dormant Projects, H1 2015 80

Chemotherapy Induced Nausea and Vomiting-Discontinued Products, H1 2015 81

List of Figures

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2015 9

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 33

Assessment by Combination Products, H1 2015 34

Number of Products by Top 10 Targets, H1 2015 35

Number of Products by Stage and Top 10 Targets, H1 2015 35

Number of Products by Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Top 10 Routes of Administration, H1 2015 39

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40

Number of Products by Stage and Top 10 Molecule Types, H1 2015 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acacia Pharma Ltd.

Aphios Corporation

Genovate Biotechnology Co., LTD.

Helsinn Holding S.A.

Heron Therapeutics, Inc.

INSYS Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Merck & Co., Inc.

RedHill Biopharma Ltd.

Shin Nippon Biomedical Laboratories, Ltd.

Sparsha Pharma International Pvt. Ltd.

Suda Ltd

Teikoku Pharma USA, Inc.

Tesaro, Inc.

Chemotherapy Induced Nausea and Vomiting Therapeutic Products under Development, Key Players in Chemotherapy Induced Nausea and Vomiting Therapeutics, Chemotherapy Induced Nausea and Vomiting Pipeline Overview, Chemotherapy Induced Nausea and Vomiting Pipeline, Chemotherapy Induced Nausea and Vomiting Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com